New Points of Departure for More Global Influenza Vaccine Use
Each year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the dru...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/8/3/410 |
id |
doaj-134ef591f5364a2792ad6e4433b5fe58 |
---|---|
record_format |
Article |
spelling |
doaj-134ef591f5364a2792ad6e4433b5fe582020-11-25T02:48:06ZengMDPI AGVaccines2076-393X2020-07-01841041010.3390/vaccines8030410New Points of Departure for More Global Influenza Vaccine UseIrina Kiseleva0Department of Virology, Federal State Budgetary ScYientific Institution, Institute of Experimental Medicine, 197376 St Petersburg, RussiaEach year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the drug resistance of currently circulating viruses reduce the effectiveness of prophylaxis and treatment and require the development of new broad-spectrum preparations. Furthermore, the challenge of creating a highly effective universal influenza vaccine takes on renewed intensity in the face of the COVID-19 pandemic.https://www.mdpi.com/2076-393X/8/3/410influenzainactivated vaccineslive attenuated vaccinesnext-generation vaccinessynthetic vaccinescross protectivity |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Irina Kiseleva |
spellingShingle |
Irina Kiseleva New Points of Departure for More Global Influenza Vaccine Use Vaccines influenza inactivated vaccines live attenuated vaccines next-generation vaccines synthetic vaccines cross protectivity |
author_facet |
Irina Kiseleva |
author_sort |
Irina Kiseleva |
title |
New Points of Departure for More Global Influenza Vaccine Use |
title_short |
New Points of Departure for More Global Influenza Vaccine Use |
title_full |
New Points of Departure for More Global Influenza Vaccine Use |
title_fullStr |
New Points of Departure for More Global Influenza Vaccine Use |
title_full_unstemmed |
New Points of Departure for More Global Influenza Vaccine Use |
title_sort |
new points of departure for more global influenza vaccine use |
publisher |
MDPI AG |
series |
Vaccines |
issn |
2076-393X |
publishDate |
2020-07-01 |
description |
Each year, influenza causes a significant acute respiratory disease burden. In addition, influenza pandemics periodically occur. Annual vaccination is the best tool for influenza prevention, but its effectiveness can vary from year to year. The narrow specificity of conventional vaccines and the drug resistance of currently circulating viruses reduce the effectiveness of prophylaxis and treatment and require the development of new broad-spectrum preparations. Furthermore, the challenge of creating a highly effective universal influenza vaccine takes on renewed intensity in the face of the COVID-19 pandemic. |
topic |
influenza inactivated vaccines live attenuated vaccines next-generation vaccines synthetic vaccines cross protectivity |
url |
https://www.mdpi.com/2076-393X/8/3/410 |
work_keys_str_mv |
AT irinakiseleva newpointsofdepartureformoreglobalinfluenzavaccineuse |
_version_ |
1724749966129233920 |